Breaking through the limits of cancer medicine

Gordon Mills, M.D., Ph.D., the new director of precision oncology at Oregon Health & Science University, outlines a vision for the field. Photo: Gordon Mills, M.D., Ph.D. (OHSU/Kristyna...

Zeroing in on drug combos against a formidable form of leukemia

A heat map by Kurtz et al. comparing the sensitivities of leukemia cells to drug combinations. Darker red indicates drug combinations exhibiting higher efficacy than either agent alone. Targeted...

Riveting survival stories from the early clinical trials of Gleevec

Medicine had never seen anything like it before, Brian Druker, M.D., recalled. "These are people who’d been told to get their affairs in order. And now their blood counts are normal," the...

The cancer drug that “changed everything”

Understanding the earliest drivers of cancer formation can lead to less toxic and more effective treatments. It transformed the outlook for people diagnosed with chronic myeloid leukemia. A...

Enterprising cancer treatment ideas nurtured with pilot funds

Finding new treatment targets for aggressive prostate cancer, lymphoma and leukemia. Visualizing how breast tumors grow resistant to drug therapy. Using mobile phone sensors to track symptoms...

This is what a ‘game changing’ cancer therapy looks like

Life expectancy in patients with chronic myeloid leukemia has soared to a level almost equal to that of the general population, according to a Swedish study quantifying the life-saving impact of...

Engineering precision in cancer early detection

Sadik Esener, Ph.D., is the engineer tapped to lead a major new cancer early detection program at the OHSU Knight Cancer Institute. Medical science has come up with only a few ways to detect...

Genomic drivers of a poorly understood kidney cancer

Researchers have identified many of the altered genes and cell signaling pathways that drive papillary renal cell carcinoma, a poorly understood form of cancer that accounts for about 15 percent of...